# A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

> **NCT02901483** · PHASE1,PHASE2 · TERMINATED · sponsor: **PharmaEngine** · enrollment: 12 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** PEP503
- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02901483
- **Lead sponsor:** PharmaEngine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-11
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-17
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** bussiness reason
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02901483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02901483, "A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02901483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*